SLS-005

Small molecule

SSeelos Therapeutics, Inc.

SLS-005 is one of 13 small molecule programs targeting Cerebellar Ataxia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebellar AtaxiaActive, not recruiting

Cerebellar AtaxiaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Cerebellar Ataxia

#DrugCompanyPhaseTrials

Fampridine

Biogen

Phase 3

1 2

Rilutek

AAzurity Pharmaceuticals

Phase 2

3 3

Lithobid

SSolvay Pharmaceuticals

Phase 2

2 4

Tasigna

AAzurity Pharmaceuticals

Phase 2

1 5

Asceniv

CSL Behring

Phase 1

1 6

Ivig

Argenx

Phase 2

1 7

Stemchymal

SSteminent Biotherapeutics Inc.

Phase 2

2 8

CAD-1883

CCadent Therapeutics

Phase 2

1 9

Ampyra

MMerz Pharmaceuticals GmbH

Preclinical

1 10

Troriluzole

BBiohaven Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2/3Recruiting

Trial

NCT04297683

Clinical

Trials by Indication[1]

Trial2 trials

HEALEY ALS Platform Trial - Master Protocol

Recruiting·MMerit E. Cudkowicz, MD·Phase 2/3·NCT04297683·1,500 enrolled

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

Completed·MMerit E. Cudkowicz, MD·Phase 2/3·NCT05136885·161 enrolled

Alzheimer's Disease1 trial

SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease

Withdrawn·SSeelos Therapeutics, Inc.·Phase 2·NCT05332678

Cerebellar Ataxia1 trial

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated·SSeelos Therapeutics, Inc.·Phase 2/3·NCT05490563·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SLS-005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SLS-005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SLS-005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seelos Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SSeelos Therapeutics, Inc.

SLS-005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Trial2 trials

Alzheimer's Disease1 trial

Cerebellar Ataxia1 trial

References

Drug Info

Quick Facts

Related News